ExpreS2ion’s proprietary platform used for successful production of another transmission blocking malaria vaccine candidate

Report this content

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that a recently published scientific article in Nature Communications on the Pfs48/45 malaria vaccine candidate adds further evidence to support that the ExpreS2 platform is an excellent tool for producing transmission blocking malaria vaccines. This is a promising class of next generation vaccines, which is developed with substantial support from the Bill and Melinda Gates foundation.

The article is cowritten by researchers at the University of Oxford and ExpreS2ion, who are also engaged in the development of the RH5.1 malaria vaccine candidate produced using the ExpreS2 platform, that is currently being evaluated in a phase 2a clinical trial.

“We are excited to be working with University of Oxford on their transmission blocking malaria vaccine candidates. The recently published article adds further support to the use of our ExpreS2 platform for production of this class of malaria vaccines” says ExpreS2ion’s CEO Dr. Steen Klysner.

The scientific article on the use of ExpreS2 to produce a transmission blocking malaria vaccine candidate was published in Nature Communications. It is titled “Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody” and can be accessed via the following link: https://www.nature.com/articles/s41467-018-06340-9.pdf

The Company’s ExpreS2 platform is also used by the PAMVAC consortium for the development and production of their placental malaria vaccine candidate, that is currently in a phase 1a/1b clinical trial. The clinical part of this study is completed, and the results are currently being evaluated.


Malaria is a major global health problem with 3.2 billion people living at risk of malaria infection. In 2015, malaria was thought to have caused 429,000 deaths, most of which (70%) occurred in children under five years old (WHO, 2016, http://www.who.int/malaria/media/world-malaria-report-2016/en/). In a malaria market assessment study by the Boston Consulting Group sponsored by the Malaria Vaccine Initiative, the malaria vaccine demand was estimated to be translated into a global market value of up to $400M per year.

Certified Adviser 

Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

For further information about ExpreS2ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.